OcellO announces two year agreement with Merus to provide in vitro research services for MCLA-158 and other undisclosed Biclonics® programs

NEXT STORY
VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update
PREV STORY
Madrigal Pharmaceuticals Initiates Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New two-year data show Roche’s Evrysdi (risdiplam) continues to demonstrate improvement or maintenance of motor function in people aged 2-25 with Type 2 or Type 3 Spinal Muscular Atrophy (SMA)

author_avatar
NASDAQ Market News

Orion Corporation and Alligator Bioscience announce immuno-oncology research collaboration and license agreement

author_avatar
NASDAQ Market News

Mateon Announces Achievement of Milestone Under Licensing of OT-101/IL-2 Combination to Autotelic BIO

author_avatar
NASDAQ Market News